

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Aboyans Victor	No	
Bartelink Marie-Louise	No	
Baumgartner Iris	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Covidien : consultant - Abbott - lecture fees : endovascular - Medtronic : endovascular, consultant - Sanofi Aventis : speakers fee, secondary prevention - Astra Zeneca : steering committee <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronic : research grant, endovascular - Abbott - lecture fees : research grant, endovascular - Sanofi Aventis : research grant, secondary prevention
Clement Denis	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Astra Zeneca : Hypertension - Menarini : Hypertension - Solvay : Hypertension
Collet Jean-Philippe	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban - Nycomed : aspirin - Sanofi Aventis : clopidogrel - Roche Diagnostics : hypersensitive troponin - Astra Zeneca : prasugrel - Eli Lilly : prasugrel <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Sanofi-Aventis : clopidogrel - Cordis and Medtronic : platelet function testing

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Cremonesi Alberto	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Invatec AG, Frauenfeld, Switzerland : Carotid artery stenting</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Invatec AG, Frauenfeld, Switzerland : Peripheral drug eluting balloon</p>
De Carlo Marco	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott Vascular : peripheral and carotid interventions</p>
Erbel Raimund	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis-Investigator : Rasilez - Astra Zeneca - speaker fees : Rosuvastatin - Biotronik-Advisory board : Stents</p> <p>D - Research funding (departmental or institutional). - Biotronik : Pacemakers</p>
Fowkes Gerry	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi-Aventis : clopidogrel</p> <p>D - Research funding (departmental or institutional). - Bayer Healthcare : aspirin</p>
Heras Magda	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Rovi : Ivabradina - Menarini : Ranolazine - Astra Zeneca : Ticagrelor</p> <p>D - Research funding (departmental or institutional). - GSK : Fondaparinux, eptifibatide</p>
Kownator Serge	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra zeneca, Bayer, Boehringer Ingelheim, BMS, Daiishi Sankyo, Menarini, MSD, Novartis, Pfizer, Sanofi Aventis, Servier: cardiovascular risk</p>
Minar Erich	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer Ingelheim : Data safety and monitoring board - Boehringer Ingelheim (member of data safety and monitoring board for RECOVER and REMEDY) and Bayer (local advisory board) and Abbott (speaker fee) : New antithrombotic drugs (Boehringer-Ingelheim and Abbott) and Stents(Abbott)</p>

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Minar Erich	Yes	<ul style="list-style-type: none"> - Bayer - speaker fees; advisory board fees (rivaroxaban) : Rivaroxaban - Abbott - lecture fees : Stents
Ostergren Jan	Yes	<ul style="list-style-type: none"> D - Research funding (departmental or institutional). - Novartis : Aliskiren
Poldermans Don	Yes	<ul style="list-style-type: none"> D - Research funding (departmental or institutional). - Maquette : Balloon pump device - Merck : drugs - Novartis : drugs - Baxter : drugs - Medtronic : Reveal device
Riambau Vicente	Yes	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : aortic endografts - Cook Medical : Aortic endografts - Bolton Medical : Aortic endografts B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - W.L. Gore & associates : Aortic endografts
Roffi Marco	Yes	<ul style="list-style-type: none"> A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Antiplatelet therapy D - Research funding (departmental or institutional). - Abbott : devices - Boston Scientific : devices - Medtronic : devices - Biotronik : devices - Cordis : devices

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Rother Joachim	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban - Lundbeck : CEPO, desmoteplase - Sanofi Aventis : clopidogrel, dronedarone - Bayer Healthcare : rivaroxaban - Boehringer Ingelheim : thrombolysis, dabigatran
Sievert Horst	Yes	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Access-Closure : arterial closure device - Arstasis : arterial closure device - AGA medical : closure devices for congenital and structural heart diseases - Occlutech : closure devices for congenital heart diseases - Coherex : closure devices for congenital heart diseases - Lifetech : closure devices for congenital heart diseases - NDC : closure devices for congenital heart diseases - NMT : closure devices for congenital heart diseases - Ovalis : closure devices for congenital heart diseases - pfm : closure devices for congenital heart diseases - Spectranetics : device for angiologic interventions - Trivascular : device for angiologic interventions - Cardiokinetix : device for cardiologic intervention - Cardiomems : device for cardiologic intervention - Epitek : device for cardiologic intervention - Evalve : device for cardiologic intervention - Medinol : device for cardiologic intervention - Viacor : device for cardiologic interventions

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Sievert Horst	Yes	<ul style="list-style-type: none"> - FlowCardia : device for cardiologic interventions - HLT : device for cardiologic interventions - Osprey : device for cardiologic interventions - Percardia : device for cardiologic interventions - Recor : device for cardiologic interventions - Sadra : device for cardiologic interventions - Trireme : device for cardiologic interventions - Sorin : device for cardiologic/angiologic interventions - Contego : device for carotid intervention - Endotex : device for carotid intervention - Lumen Biomedical : device for carotid intervention - Kensey Nash : device for carotid intervention - PendraCare : device for carotid interventions - CSI : device for peripheral intervention - Endocross : device for peripheral intervention - Kyoto Medical : device for peripheral intervention - Lutonix : device for peripheral intervention - OAS : device for peripheral interventions - Pathway : device for peripheral interventions - Veryan : device for peripheral treatment - SquareOne : device for renal intervention (2011) - Boston Scientific : devices for angiologic/cardiologic interventions - Angiomed : devices for angiologic/cardiologic interventions - Ev3 : devices for angiologic/cardiologic interventions

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Sievert Horst	Yes	<ul style="list-style-type: none"> - Bridgepoint : devices for cardiologic intervention - Medtronic : devices for cardiologic/angiologic interventions - Guidant : devices for cardiologic/angiologic interventions - Gore : devices for cardiologic/angiologic interventions - Bard : devices for peripheral interventions - Avinger : devices for peripheral interventions - Atrium : devices for treatment of coarctations - Rox Medical : interventional treatment of COPD - Ardian : renal denervation
Tendera Michal	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bayer - consulting or lecture fees : Aspirin, Rivaroxaban - Bayer - investigator fee : Aspirin, Rivaroxaban - Amgen : Darbopietin <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier - speaker fees; investigator fees : Ivabradine, Phase II investigational products - TIMI group : Rivaroxaban <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - TIMI group : Rivaroxaban - Servier : Unrestricted grant, Ivabradine, Phase II investigational product
Van Sambeek Marc R H M	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Medtronic : speaker fee <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Medtronic : research funding
Zeller Thomas	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Bard : PAD - Daiichi-Sankyo : PAD - Invatec AG, Frauenfeld, Switzerland : PAD

Guidelines on Peripheral Artery Disease (TF30) - Task Force Members and Additional Contributors

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Zeller Thomas	Yes	<ul style="list-style-type: none"> - Spectranetics : PAD - Cook Medical : PAD - W.L. Gore & associates : PAD - Abbott Vascular : PAD - Cordis : PAD - Biotronik - speakers fees : PAD - Biotronik - Clinical Trial : PAD - Terumo : PAD - Ardian : renal denervation <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Spectranetics : PAD - Volcano : Renal arter stenosis <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Cook Medical : DES PAD

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Agewall Stefan	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - AstraZeneca: Acute Coronary Syndrome (ACS)
Blinc Ales	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare - AstraZeneca - Eli Lilly - Krka, d.d. C1 - Research funding (departmental or institutional) - Krka, d.d.: Prevention of ischemic events in patients with peripheral arterial disease
Bulvas Miroslav	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic - Straub Medical - Bohemia Medical
Cosentino Francesco	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - AstraZeneca: Cardiovascular Diseases (CVD) - Takeda: CVD and Type 2 Diabetes Mellitus (T2DM) - Bayer: CVD and T2DM - Bristol-Myers Squibb: CVD and T2DM - Chiesi: CVD - Pfizer: CVD - Abbott: CVD, Dyslipidemia, and T2DM - Roche: CVD and T2DM C1 - Research funding (departmental or institutional) - Rome foundation: CVD and T2DM - University "Sapienza" of Rome: CVD and T2DM
De Backer Tine	No	
Gottsäter Anders	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
		<ul style="list-style-type: none"> - AstraZeneca - Boehringer-Ingelheim - Bristol-Myers Squibb - LEO Pharma - MSD - Novartis - Otsuka Pharma - Pfizer - Sanofi-Aventis <p>C1 - Research funding (departmental or institutional)</p> <ul style="list-style-type: none"> - No funding from pharmaceutical companies. Only from governmental and regional organizations and local research funds at the hospital <p>C2 - Research funding (personal)</p> <ul style="list-style-type: none"> - No funding from pharmaceutical companies. Only from governmental and regional organizations and local research funds at the hospital.
Gulba Dietrich	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim: Antithrombotic and Fibrinolytic - Bayer Healthcare: Antithrombotic - AstraZeneca: Antithrombotic - Eli Lilly: Antiplatelet agent - Daiichi Sankyo: Antiplatelet agent - TMC: Antithrombotic agent - Sanofi-Aventis: Antithrombotic agent - GlaxoSmithKline: Antiplatelet agent
Guzik Tomasz	No	
Jönsson Björn	Yes	<p>5 - Any other potential interest to be declared related to the currency ESC position held</p> <ul style="list-style-type: none"> - 50% ownership of company developing tools for vascular diagnosis. No commercial product. No financial revenue so far
Késmárky Gábor	No	

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Kitsiou Anastasia	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Menarini: Hypertension - AstraZeneca: Acute Coronary Syndromes - Sanofi-Aventis: Acute Coronary Syndromes
Kuczmik Wacław	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - EV3: SilverHawk
Lytken Larsen Mogens	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - AstraZeneca: Statins - MSD: Lipid lowering drugs - Pfizer: Statins - Roche: Lipid lowering drugs
Madaric Juraj	No	
Mas Jean-Louis	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - AstraZeneca - Bristol-Myer-Squibb - Bayer - Boehringer-Ingelheim - Daiichi Sankyo - Pfizer - Sanofi-Aventis - Servier - Takeda

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
McMurray John	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc</p> <ul style="list-style-type: none"> - Novartis: NAVIGATOR, ASPIRE, ALTITUDE, PARADIGM-HF, VIVIDD (Steering Committee*) - Sanofi-Aventis: ELIXA (Steering Committee*) - Bristol-Myers Squibb/Pfizer: ARISTOTLE (Steering Committee*) - Amgen: TREAT, RED-HF (Steering Committee*) - Scios: ASCEND-HF (Steering Committee*) - Pfizer: EMPHASIS-HF (Steering Committee*) - Roche: Dal-Outcomes (Steering Committee*), ALECARDIO (DSMB) - Amylin/Eli-Lilly: EXSCEL (DSMB) - Merck: TECOS (DSMB) <p>*Payments made to Glasgow University</p>
Micari Antonio	No	
Mosseri Morris	Yes	<p>C1 - Research funding (departmental or institutional)</p> <ul style="list-style-type: none"> - Pharma-Clinical / Medtronic: Endeavor Stent - Quintiles / Roche: Increase of HDL Levels - Medpace / Kai: Preserving myocardium during acute MI - Hemcon Medical: Hemostasis after femoral puncture - Quintiles / Taby: Prasugrel in patients with ACS not undergoing PCI - Natwest: Thrombin receptor blocker in chronic IHD - PPD / TIMI52: Darbapladib in ACS - Sanofi-Aventis / Origin: Insulin Lantus - Icon Clinical / Tracer: Thrombin receptor blocker in ACS - Icon Clinical / Current / Sanofi-Aventis: High dose Clopidogrel in ACS

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Müller Christian	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Abbott - Brahms - Roche <p>C1 - Research funding (departmental or institutional)</p> <ul style="list-style-type: none"> - Abbott - Roche - Brahms
Naylor Ross	No	
Norrving Bo	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Syngis: neuroprotection, G-CSF (Steering cte) - Allergan: Spasticity, Botox (advisory Board) - Phototera: Laser therapy (DSMB) - Servier: Antiplatelet therapy (endpoint adjudication cte) - Bayer: Stroke prevention <p>6 - Membership or affiliation in political/pressure group associations related to the field of cardiology</p> <ul style="list-style-type: none"> - President World Stroke Organization
Oto Öztekin	No	
Pasiński Tomasz		<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi-Aventis: Dronedarone - Bristol-Myers Squibb: Apixaban <p>4 - Employment in healthcare industry (full or part time)</p> <ul style="list-style-type: none"> - Chief of Scientific Council of Polish HTA Agency
Plouin Pierre-François	No	

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Ribichini Flavio	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Abbott vascular: Coronary - Medtronic: Coronary
Ricco Jean-Baptiste	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - B Braun: Vena cava filtration C2 - Research funding (personal) <ul style="list-style-type: none"> - Maquet SA: Antimicrobial prosthetic vascular grafts
Ruilope Luis	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none"> - Daiichi Sankyo: Hypertension and renal disease - Takeda: Hypertension - Novartis: Hypertension and renal disease - AstraZeneca: Hypertension and Antiplatelet therapy - Servier: Hypertension - Menarini: Hypertension
Schmid Jean-Paul	Yes	C2 - Research funding (personal) <ul style="list-style-type: none"> - Storz Medical: Shock Wave therapy
Schwehr Udo	No	
Sol Berna G. M.	No	

Guidelines on the diagnosis and treatment of peripheral artery disease (TF30) Document Reviewers

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Sprynger Muriel	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc</p> <ul style="list-style-type: none"> - Bayer: Investigator (Einstein) + advisory board - Saint Jude Medical, - Daiichi-Sankyo, - Sanofi-Aventis, - Pfizer, - Leo Pharma, - GlaxoSmithKline, - Boehringer-Ingelheim <p>6 - Membership or affiliation in political/pressure group associations related to the field of cardiology</p> <ul style="list-style-type: none"> - French Society of Vascular Medicine (SFMV): Speaker + Member of the Working Group on Cervicoencephalic arteries and on Peripheral Artery Disease - ESC- EAE : Member + Webinar - Belgian Working Group of Angiology (BWGA): Secretary - Belgian Society of Thrombosis-Haemostasis (BSTH): Board member - International Union of Angiology : Member- past National Delegate - French College of Vascular Pathology (CFPV): Member - Belgian Committee of Hypertension (BSH): Delegate
Tiefenbacher Christiane	Yes	<p>6 - Membership or affiliation in political/pressure group associations related to the field of cardiology</p> <ul style="list-style-type: none"> - German Society of Cardiology - German Society of Angiology (Speaker)
Tsioufis Konstantinos	No	
Van Damme Hendrik	No	



ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Auricchio Angelo	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Biologics Delivery Systems, Cordis Corporation a Johnson & Johnson company : Biological Therapy- Philips : Cardiac Imaging- Merck : Drugs- Biotronik : Implantable Cardiac Electronic Device- EBR Systems : Implantable Cardiac Electronic Device- Impulse Dynamics : Implantable Cardiac Electronic Device- Medtronic : Implantable Cardiac Electronic Device- Sorin : Implantable Cardiac Electronic Device- St. Jude Medical : Implantable Cardiac Electronic Device- Abbott : Implantable Cardiac Electronic Device
Baumgartner Helmut	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Actelion : Bosentan for PAH treatment in congenital heart disease- AGA : Devices for catheter treatment of congenital heart defects B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Edwards Lifesciences : transcatheter valve implantation
Bax Jeroen	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Heart.org : Education- Servier : Farma- Astra Zeneca : Farma- GE Healthcare : Imaging- Lantheus : Imaging- Philips : Imaging- St Jude Medical : Pacing



ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Bax Jeroen	Yes	<ul style="list-style-type: none"> - Medtronic : Pacing - Impulse Dynamics : Pacing - Biotronik : Pacing - Boston Scientific : Pacing D - Research funding (departmental or institutional). <ul style="list-style-type: none"> - Servier : Farma - Edwards Lifesciences : Heart Valves - Lantheus : Imaging - GE Healthcare : Imaging - Boston Scientific : Pacing - Medtronic : Pacing - St Jude Medical : Pacing - Biotronik : Pacing
Ceconi Claudio	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Pharmaceutical
Deaton M Christi	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - St Jude Ltd : Cath lab - speaker X 1 - Daiichi Sankyo : consultant for patient adherence 2009-10 - Eli Lilly : consultant for patient adherence 2009-10 D - Research funding (departmental or institutional). - Novo Nordisk : medicines for diabetes
Fagard Robert	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : perindopril; support for organisation of scientific meeting
Funk-Brentano Christian	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pierre-Fabre : Cardiac Safety of non-cardiovascular products



ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Funck-Brentano Christian	Yes	<ul style="list-style-type: none"> - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Sigma-Tau (Italy) : Cardiac Safety of an antimalarial drug - Santhera (CH) : Cardiac Safety of an antimalarial drug - MMV (CH) : Cardiac Safety of an antimalarial drug - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety - CEPHALON : DSMB in an oncology phase IIb trial - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel
Hasdai David	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Enoxaparin
Hoes Arno	Yes	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer Healthcare : unrestricted grant for diagnostic kits in suspected cardiovascular disease - Abbott Laboratories : unrestricted grant for diagnostic kits in suspected cardiovascular disease - Roche : unrestricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome
Knuuti Juhani	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Lantheus Inc : Imaging tracers <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Bayer : Development of imaging agents - GE Healthcare : Development of imaging agents - Lantheus : Development of imaging agents - Novartis : Development of imaging agents - Roche : Drugs for brain diseases
Kolh Philippe H	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p>



ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Kolh Philippe H	Yes	<ul style="list-style-type: none"> - Merck Sharp & Dohme : Antiarrhythmic agents - Bristol Myers Squibb : Antiplatelet agents - Astra Zeneca : Antiplatelet agents - Regado Biosciences : Antithrombotic agents - Abbott - lecture fees : coronary stents <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Antistaphylococcic vaccine <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Cardiac valves - Medtronic : Cardiac valves - St Jude Medical : Cardiac valves - Siemens Healthcare : Imaging - Johnson & Johnson : Thoracoscopic devices
McDonagh Theresa	Yes	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> - Servier - speaker fee : Ivabridine <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Biotronik - Clinical Trial : CRT
Poldermans Don	Yes	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> - Maquette : Balloon pump device - Merck : drugs - Novartis : drugs - Baxter : drugs - Medtronic : Reveal device



ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Popescu Bogdan Alexandru	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GE Healthcare : Imaging
Reiner Zeljko	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : anticoagulants - Abbott - lecture fees : antilipemics - Astra Zeneca : antilipemics - Merck Sharp & Dohme : antilipemics - Pfizer : antilipemics
Sechtem Udo	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer Ingelheim : Anticoagulation - Daiichi Sankyo : Antiplatelet therapy - Novartis : Drugs - General Electric : Imaging - Siemens Healthcare : Imaging B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : Imaging devices - Johnson & Johnson : Stents
Simes Per Anton	Yes	D - Research funding (departmental or institutional). - Bayer : clinical studies atrial fibrillation investigator fee - Johnson & Johnson : investigator fee, clinical study, atrial fibrillation - MSD : investigator fee clinical studies hyperlipidemia, SCAD - Glaxo Smith Kline : investigator fee, clinical study , SCAD - Servier : investigator fee, clinical study, coronary artery disease - Jansen-Cilag : investigator fee, clinical study, diabetes CVD - Boehringer Ingelheim : investigator fee, clinical study, AF



ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
Torbicki Adam	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Boehringer-Ingelheim : anticoagulation- Sanofi Aventis : anticoagulation- Pfizer : anticoagulation, pulmonary hypertension- Lilly : pulmonary hypertension- Actelion : pulmonary hypertension- Bayer Healthcare : pulmonary hypertension, anticoagulation
Vahanian Alec	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Boehringer Ingelheim : Valve prostheses- Siemens Healthcare : Valve prostheses- Valtech : Valve prostheses- Edwards Lifesciences : Valve prostheses- Abbott : Valve prostheses- Medtronic - Advisory Board : Valve prostheses
Windecker Stephan	Yes	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. <ul style="list-style-type: none">- Astra Zeneca : Antiplatelet drug- Eli Lilly : Antiplatelet drug- Abbott : Stent- Biosensors : Stent- Biotronik : Stent- Boston Scientific : Stent- Cordis : Stent- Medtronic : Stent D - Research funding (departmental or institutional). <ul style="list-style-type: none">- Medtronic : Stent



EUROPEAN
SOCIETY OF
CARDIOLOGY®

ESC Committee for Practice Guidelines 2010-2012

Expert	Relationship with Industry	Type of relationship with industry Financial declaration
		- Abbott : Stent - Biosensors : Stent - Cordis : Stent

This table represents the relevant relationships of the above experts with Industry and other entities that were reported to us at the time of publication of the guidelines.